PT1257275E - Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco - Google Patents

Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco

Info

Publication number
PT1257275E
PT1257275E PT01907722T PT01907722T PT1257275E PT 1257275 E PT1257275 E PT 1257275E PT 01907722 T PT01907722 T PT 01907722T PT 01907722 T PT01907722 T PT 01907722T PT 1257275 E PT1257275 E PT 1257275E
Authority
PT
Portugal
Prior art keywords
antagonist
facilitate
stop
preparation
central
Prior art date
Application number
PT01907722T
Other languages
English (en)
Portuguese (pt)
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PT1257275E publication Critical patent/PT1257275E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT01907722T 2000-02-09 2001-02-07 Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco PT1257275E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
PT1257275E true PT1257275E (pt) 2005-07-29

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01907722T PT1257275E (pt) 2000-02-09 2001-02-07 Utilizacao de um antagonista dos receptores de canabinoides centrais para a preparacao de medicamentos uteis para facilitar a paragem do consumo de tabaco

Country Status (32)

Country Link
US (2) US6930122B2 (enExample)
EP (1) EP1257275B1 (enExample)
JP (2) JP2003522145A (enExample)
CN (1) CN1250220C (enExample)
AR (1) AR028505A1 (enExample)
AT (1) ATE292467T1 (enExample)
AU (1) AU781827B2 (enExample)
BG (2) BG110386A (enExample)
BR (1) BR0108126A (enExample)
CA (1) CA2397262C (enExample)
CZ (1) CZ296685B6 (enExample)
DE (1) DE60109903T2 (enExample)
DK (1) DK1257275T3 (enExample)
EE (1) EE04836B1 (enExample)
ES (1) ES2240416T3 (enExample)
FR (1) FR2804604B1 (enExample)
HU (1) HU225328B1 (enExample)
IL (1) IL150710A0 (enExample)
IS (1) IS6450A (enExample)
MX (1) MXPA02007766A (enExample)
NO (1) NO324521B1 (enExample)
NZ (1) NZ519924A (enExample)
PL (1) PL201685B1 (enExample)
PT (1) PT1257275E (enExample)
RS (1) RS50404B (enExample)
RU (1) RU2257207C2 (enExample)
SI (1) SI1257275T1 (enExample)
SK (1) SK284952B6 (enExample)
TW (1) TWI243677B (enExample)
UA (1) UA72783C2 (enExample)
WO (1) WO2001058450A2 (enExample)
ZA (1) ZA200205317B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
CN1568432A (zh) 2001-08-13 2005-01-19 霍尼韦尔国际公司 使用沟槽为晶片承载的半导体器件提供电流控制
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7390835B2 (en) * 2003-10-30 2008-06-24 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
WO2007084450A2 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
WO2009005646A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
NO20023765D0 (no) 2002-08-08
FR2804604A1 (fr) 2001-08-10
UA72783C2 (en) 2005-04-15
FR2804604B1 (fr) 2005-05-27
HU225328B1 (en) 2006-09-28
CZ296685B6 (cs) 2006-05-17
EE04836B1 (et) 2007-06-15
HUP0300237A3 (en) 2003-09-29
ATE292467T1 (de) 2005-04-15
MXPA02007766A (es) 2002-10-11
SK11292002A3 (sk) 2003-02-04
US6930122B2 (en) 2005-08-16
WO2001058450A3 (fr) 2002-04-25
HUP0300237A2 (hu) 2003-07-28
SK284952B6 (sk) 2006-03-02
CZ20022698A3 (cs) 2002-11-13
CN1250220C (zh) 2006-04-12
US20030087933A1 (en) 2003-05-08
PL201685B1 (pl) 2009-04-30
DE60109903T2 (de) 2006-02-09
BR0108126A (pt) 2003-01-28
US20050187253A1 (en) 2005-08-25
WO2001058450A2 (fr) 2001-08-16
BG65856B1 (bg) 2010-03-31
RU2002118309A (ru) 2004-02-20
DK1257275T3 (da) 2005-08-08
TWI243677B (en) 2005-11-21
RS50404B (sr) 2009-12-31
AR028505A1 (es) 2003-05-14
NO324521B1 (no) 2007-11-12
JP2010018622A (ja) 2010-01-28
AU781827B2 (en) 2005-06-16
BG110386A (en) 2009-09-30
ZA200205317B (en) 2003-09-04
EP1257275A2 (fr) 2002-11-20
PL358221A1 (en) 2004-08-09
IL150710A0 (en) 2003-02-12
NO20023765L (no) 2002-10-09
ES2240416T3 (es) 2005-10-16
EP1257275B1 (fr) 2005-04-06
CA2397262A1 (en) 2001-08-16
DE60109903D1 (de) 2005-05-12
SI1257275T1 (en) 2005-10-31
YU59002A (sh) 2005-07-19
HK1051140A1 (en) 2003-07-25
CN1406128A (zh) 2003-03-26
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
RU2257207C2 (ru) 2005-07-27
JP2003522145A (ja) 2003-07-22
AU3562001A (en) 2001-08-20
NZ519924A (en) 2005-01-28
BG106946A (bg) 2003-05-30
CA2397262C (en) 2007-09-11

Similar Documents

Publication Publication Date Title
PL358221A1 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
ATE480539T1 (de) Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
CO5160257A1 (es) La n-piperidino-5-(4-bromofenil)-1-(2,4-diclorofenil)-4-etilpirazol-3-carboxamida, sus sales, su preparacion y las composiciones farmaceuticas que la contienen
YU47099A (sh) Farmaceutski preparat za oralno unošenje derivata n-piperidino-3-pirazolkarboksamida, njegovih soli i njihovih solvata
AU2000279624A1 (en) Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
CY1112078T1 (el) Χρηση των ανταγωνιστων του cb1 υποδοχεα για την παρασκευη ενος σκευασματος που θα χρησιμοποιηθει για τη θεραπεια των ηπατικων νοσων
EA200300999A1 (ru) Хронотерапевтические дозированные формы
JP2003522145A5 (enExample)
DZ3358A1 (fr) Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
MXPA03002295A (es) Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
BR0011174A (pt) Composições, compostos, compostos isolados e métodos para controlar pestes
FR2861992B1 (fr) Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
AU2002318801A1 (en) Herbicide containing substituted pyrazole derivative as active ingredient
AR033261A1 (es) Antagonistas de nmda para el tratamiento de enfermedades adictivas
TW200640458A (en) Use of a pyrazole derivative for preparing medicinal products that are of use in the prevention and treatment of kidney diseases
TH62253A (th) การใช้เซ็นทรัลแคนนาบินอยด์รีเซพเตอร์แอนแทกโกนิสต์ เพื่อการเตรียมผลิตภัณฑ์ยาซึ่งใช้ประโยชน์เพื่อการช่วยให้เลิกสูบบุหรี่
TH0001002776B (th) สารประกอบอินดาโซลและองค์ประกอบทางเภสัชภัณฑ์ในการยับยั้งโปรตีนไคเนสและวิธีใช้ประโยชน์
HK1050531A (en) New neurokinin antagonists for use as medicaments